TY - JOUR
T1 - Protocol for Therapeutic Drug Monitoring Within the Clinical Range Using Mid-infrared Spectroscopy
AU - Dong, Pin
AU - Li, Kezheng
AU - Rowe, David
AU - Krauss, Thomas Fraser
AU - Wang, Yue
N1 - © 2024 The Authors.
PY - 2024/12/3
Y1 - 2024/12/3
N2 - Therapeutic drug monitoring (TDM), which involves measuring drug levels in patients’ body fluids, is an important procedure in clinical practice. However, the analysis technique currently used, i.e. liquid chromatography–tandem mass spectrometry (LC–MS/MS), is laboratory-based, so does not offer the short response time that is often required by clinicians. We suggest that techniques based on Fourier transform infrared spectroscopy (FTIR) offer a promising alternative for TDM. FTIR is rapid, highly specific and can be miniaturized for near-patient applications. The challenge, however, is that FTIR for TDM is limited by the strong mid-IR absorption of endogenous serum constituents. Here, we address this issue and introduce a versatile approach for removing the background of serum lipids, proteins and small water-soluble substances. Using phenytoin, an antiepileptic drug, as an example, we show that our approach enables FTIR to precisely quantify drug molecules in human serum at clinically relevant levels (10 μg/mL), providing an efficient analysis method for TDM. Beyond mid-IR spectroscopy, our study is applicable to other drug sensing techniques that suffer from the large background of serum samples.
AB - Therapeutic drug monitoring (TDM), which involves measuring drug levels in patients’ body fluids, is an important procedure in clinical practice. However, the analysis technique currently used, i.e. liquid chromatography–tandem mass spectrometry (LC–MS/MS), is laboratory-based, so does not offer the short response time that is often required by clinicians. We suggest that techniques based on Fourier transform infrared spectroscopy (FTIR) offer a promising alternative for TDM. FTIR is rapid, highly specific and can be miniaturized for near-patient applications. The challenge, however, is that FTIR for TDM is limited by the strong mid-IR absorption of endogenous serum constituents. Here, we address this issue and introduce a versatile approach for removing the background of serum lipids, proteins and small water-soluble substances. Using phenytoin, an antiepileptic drug, as an example, we show that our approach enables FTIR to precisely quantify drug molecules in human serum at clinically relevant levels (10 μg/mL), providing an efficient analysis method for TDM. Beyond mid-IR spectroscopy, our study is applicable to other drug sensing techniques that suffer from the large background of serum samples.
U2 - 10.1021/acs.analchem.4c03864
DO - 10.1021/acs.analchem.4c03864
M3 - Article
SN - 0003-2700
VL - 96
SP - 19021
EP - 19028
JO - Analytical Chemistry
JF - Analytical Chemistry
IS - 48
ER -